You are here
Final Approval Granted for Generic Equivalent of Amaryl Tablets
May 30, 2014
PITTSBURGH, Nov. 29 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE:MYL) today announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glimepiride Tablets, 1 mg, 2 mg, and 4 mg. Glimepiride Tablets are the AB-rated generic equivalent of Aventis Pharmaceuticals' Amaryl(R) Tablets, which had U.S. sales of approximately $348 million for the 12-month period ending June 30, 2005, according to IMS Health.
Source: Mylan Laboratories, Inc.
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug
Declining lung cancer mortality helped fuel the progress